Kogavant

Ticagrelor, the active ingredient in Kogavant, is a P2Y12 receptor antagonist presented as an oral tablet for oral use. It is prescribed to reduce thrombotic cardiovascular events in patients with acute coronary syndrome and in those requiring secondary prevention after myocardial infarction.

GNH USA supplies Kogavant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory‑compliant shipments to global markets.

Kogavant (ticagrelor) is used as an antiplatelet therapy in the management of acute coronary syndromes and related cardiovascular conditions.

- Acute coronary syndrome: reduces the risk of cardiovascular death, myocardial infarction and stroke. - Secondary prevention after myocardial infarction: lowers the incidence of recurrent ischemic events. - Patients undergoing percutaneous coronary intervention (PCI): diminishes thrombotic complications associated with the procedure.

Ticagrelor may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dyspnea: shortness of breath, often mild to moderate. - Bleeding: including bruising, nosebleeds, and gastrointestinal hemorrhage. - Headache: transient and usually mild. - Nausea: occasional gastrointestinal upset. - Dizziness: sensation of light‑headedness. - Hypotension: mild drops in blood pressure.

Serious or Rare Side Effects: - Severe bleeding: intracranial or life‑threatening hemorrhage. - Thrombocytopenia: marked reduction in platelet count. - Hepatic injury: elevated liver enzymes or hepatitis. - Allergic reactions: rash, angioedema, or anaphylaxis. - Cardiac arrhythmias: rare cases of ventricular tachycardia.

When prescribing Kogavant, clinicians should observe several safety considerations.

- Bleeding risk assessment: evaluate for active or recent bleeding before initiation. - Dyspnea monitoring: watch for new or worsening shortness of breath. - Contraindication in pregnancy: avoid use as it is contraindicated. - Hepatic impairment: use with caution in patients with moderate liver disease. - Drug‑specific warnings: do not combine with other potent antiplatelet agents without justification. - Store at below 25°C: keep in the original pack, protect from moisture.

Ticagrelor interacts with several medicines that can alter its antiplatelet effect or increase bleeding risk.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase ticagrelor exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Concurrent use of other antiplatelet agents (e.g., high‑dose aspirin): heightens bleeding risk.

Moderate Interactions (Monitor Closely): - NSAIDs (e.g., ibuprofen): may increase gastrointestinal bleeding. - SSRIs or SNRIs (e.g., fluoxetine, venlafaxine): potential additive bleeding effect. - Anticoagulants (e.g., warfarin, DOACs): require careful monitoring of coagulation parameters.